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encompasses prompt and effective treatment to minimise morbidity and mortality, reduce transmission and prevent the emergence and 
spread of antimalarial drug resistance. Malaria is an acute illness that may progress rapidly to severe disease and death, especially in 
non-immune populations, if not diagnosed early and promptly treated with effective drugs. In this article, the focus is on malaria case 
management, addressing treatment, monitoring for parasite drug resistance, and the impact of drug resistance on treatment policies; it 
concludes with chemoprophylaxis and treatment strategies for malaria elimination in South Africa.
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Malaria case management is a 
vital component of program-
matic strategies for malaria 
control and elimination.[1-3] 
Malaria case management 
encompasses prompt and effective treatment 
to minimise morbidity and mortality, reduce 
transmission and prevent the emergence and 
spread of antimalarial drug resistance. [1-3] 
The number of malaria-related deaths is a 
key epidemiological indicator in malaria 
programmes used to evaluate performance 
in delivering effective malaria case 
management.[1]
Malaria is an acute illness that may progress 
rapidly to severe disease and death, especially 
in non-immune populations, if not diagnosed 
early and promptly treated with effective 
drugs. South Africans, including those living 
in the malaria transmission areas within the 
country, are generally non-immune. All age 
groups are therefore at risk of developing 
severe disease when infected.[4,5] 
Some important considerations to ensure 
effective malaria case management include 
availability and accessibility of antimalarial 
medicines, training of healthcare workers 
at all levels of healthcare delivery and 
dealing with the problem of antimalarial 
drug resistance.[1] In this article, the focus 
is on malaria case management, addressing 
treatment, monitoring for parasite drug 
resistance, and the impact of drug resistance 
on treatment policies; it concludes with 
chemoprophylaxis and treatment strategies 
for malaria elimination in the country.
1.  Malaria treatment 
in endemic and non-
endemic provinces 
Stratification of malaria risk areas in South 
Africa (SA) into endemic and non-endemic 
areas followed the first malaria survey in 
the country in 1921 by Park Ross, who was 
then the Assistant Secretary of Health of 
the Union of SA. Malaria-endemic parts at 
that time included the Pretoria and Durban 
districts.[6,7] Malaria endemic areas in today’s 
SA are the north-eastern part of KwaZulu-
Natal (KZN) Province and the low altitude 
regions of Mpumalanga and Limpopo 
provinces.[4,8] Although the Northern Cape 
and North West provinces are classified as 
non-endemic, malaria transmission occurs 
occasionally in areas adjacent to the Molopo 
and Orange rivers.[5] Malaria treatment 
strategies in the country differ slightly in 
endemic and non-endemic provinces.
Historically, before the advent of 
chloroquine (CQ) in the late 1940s, 
quinine was used for both treatment and 
prophylaxis, but the measures could not 
be practically extended to the population 
in the endemic areas as a whole.[6,7] During 
the 1970s, the malaria control programme 
in the country became more structured. 
Treatment was based on definitive diagnosis 
by blood smear microscopy. Malaria case 
detection and treatment was mainly through 
active case finding during house-to-house 
surveys and mass blood examination and 
between 1987 and 1990, >50% of all malaria 
cases in the country were detected by active 
case finding. [6,7] Passive case detection and 
treatment, whereby symptomatic patients at 
healthcare facilities were tested for malaria 
and treated if found positive only played 
a minor role in parasite control. In KZN 
Province, 30% of all cases in the same period 
were detected at hospitals and clinics, of 
which clinics contributed only 12%.[6,7]
In the 1990s, Sharp et al.[6,7] hypothesised 
that the relatively minor role of clinics in 
malaria case detection in the country could 
be addressed in a cost-effective manner 
by community involvement and enhanced 
service at the clinic level, effectively reducing 
the need for active case detection, and 
reducing costs. This was realised in the mid-
1990s. The adoption of the District Health 
System (DHS) based on primary healthcare 
(PHC) as the healthcare strategy for SA since 
1994,[9] the subsequent integration of passive 
diagnosis and treatment of malaria into PHC 
within the DHS[10] and the introduction of 
malaria rapid diagnostic tests (RDTs) at the 
PHC level starting in Mpumalanga Province 
in 1996,[11] revolutionised malaria case 
detection and treatment across the country. 
Passive detection and treatment of malaria at 
healthcare facilities based on a parasitological 
diagnosis with RDTs at PHC facilities and 
prompt, effective treatment is currently the 
major malaria case management strategy 
to reduce transmission in endemic areas. 
In Mpumalanga Province, passive case 
detection contributes >90% of reported total 
malaria cases each year in this era of PHC-
based DHS in SA (Fig.  1) (Mpumalanga 
Malaria Programme, unpublished data). 
Malaria diagnosis and treatment are 
provided free-of-charge at public healthcare 
facilities in both endemic and non-endemic 
provinces in the country. Evidence-based 
national or provincial guidelines informed 
by expert recommendations dictate the 
selection of preferred antimalarials, and 
drug choice policies have differed between 
provinces at various times (Table 1). Drug 
resistance surveillance data driving these 
policies are discussed later.
Currently in all endemic and non-endemic 
provinces, artemether-lumefantrine (AL) 
Table 1. Year in which first-line malaria treatment policy was changed, by province, in 
South Africa[8]
Province CQ SP Artesunate-SP AL
KwaZulu-Natal 1940s 1988 - 2001
Mpumalanga 1940s 1997 2001 2006
Limpopo 1940s 1998 - 2004
CQ = chloroquine; SP = sulphadoxine-pyrimethamine; AL = artemether-lumefantrine.
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is the recommended first-line antimalarial 
medicine for the treatment of uncomplicated 
falciparum malaria. Primaquine is used 
for radical cure of Plasmodium vivax and 
P. ovale infections.[5] Primaquine is currently 
unregistered but is available through a 
Section 21 process.[5] The second-line 
antimalarial medicines for the treatment of 
uncomplicated malaria remain oral quinine 
plus doxycycline (for adults) or clindamycin 
(for pregnant women and children under the 
age of 8 years).[5] 
Parenteral quinine has been the 
mainstay of treatment of severe malaria, 
and is still widely used in most African 
countries today. [12,13] Intravenous artesunate 
is a new parenteral antimalarial currently 
recommended by the World Health 
Organization (WHO) for the treatment of 
severe malaria in adults and children.[2,14] 
Intravenous artesunate is not yet registered 
for use in SA, but there is limited availability 
through a special access programme for 
compassionate use on a named-patient 
basis.[5] 
In the endemic provinces, treatment with 
the recommended first-line antimalarial 
medicines for uncomplicated malaria is 
accessible at any level of public healthcare 
facility, including fixed and mobile PHC 
facilities. Parenteral antimalarial medicines 
for the treatment of severe malaria are 
only available at hospital level. In the 
non-endemic provinces, antimalarial 
treatments are mostly accessible at the 
hospital level. In both endemic and non-
endemic provinces, uncomplicated malaria 
is treated at outpatient level, except for 
high-risk population groups (pregnant and 
postpartum women, infants and young 
children, the elderly (>65 years) and 
immunocompromised patients, including 
those with HIV/AIDS), who constitute a 
definite indication for hospital admission.[5] 
Severe malaria is a medical emergency that 
requires high-level hospital care; thus, for 
severe malaria patients diagnosed at PHC 
and private general practitioner facilities, 
emergency transfer to hospital is the 
norm in both endemic and non-endemic 
provinces.[5] The WHO recommends pre-
referral treatment of severe malaria with 
intramuscular artesunate, artemether, 
quinine or rectal artesunate if the transfer 
time to hospital is longer than 6 hours.[2] 
This recommendation is not implemented 
in SA. 
The major challenge facing malaria case 
management in the country is reduction of 
malaria-related deaths. Late presentation, 
lack of awareness of malaria in communities, 
and a low index of suspicion in healthcare 
workers, particularly in non-endemic 
provinces in the country,[15-18] are major 
contributing factors to malaria-related 
deaths. Even in the endemic provinces, 
case fatality rates (CFRs), defined as the 
number of deaths per 100 cases of malaria is 
above the national target of <0.5% (Fig.  2). 
The importance of continuing education 
of healthcare workers on malaria diagnosis 
and treatment[19] is critical. Regular training 
of healthcare workers at PHC and hospital 
levels on the diagnosis and management of 
uncomplicated and severe malaria is a major 
malaria case management intervention 
activity in both endemic and non-endemic 
provinces in the country. 
2.  Antimalarial drug 
resistance across SA 
and neighbouring 
countries 
Antimalarial drug resistance has greatly 
influenced malaria case management 
strategies in SA since the 1980s. Stringent 
control interventions comprising indoor 
residual spraying, periodic larviciding, and 
treatment with CQ from the late 1940s 
ensured malaria posed no severe public 
health burden until the mid-1980s.[20] 
Unfortunately by this time CQ resistance 
had reached Africa and was becoming firmly 
entrenched in southern Africa.[21] 
2.1 KZN
KZN Province first reported in vitro CQ 
resistance in 1985.[22] Under sustained CQ 
pressure, resistance spread, resulting in an 
increase in malaria cases and treatment 
failures. By 1987, 3% of all malaria-treated 
patients remained malaria-positive despite 
being treated four times with CQ.[23] The rise 
in cases and treatment failures prompted 
the KZN Department of Health to replace 
CQ with sulphadoxine-pyrimethamine (SP) 
in 1988. This policy change caused case 
numbers to gradually decline from a high of 
6 757 in 1987 to <500 by 1992. 
However, between 1993 and 2000 malaria 
case numbers began rising sharply, peaking 
in 2000 with over 40  000 cases reported in 
KZN.[24] An in vivo efficacy trial revealed 
the 42-day cure rate following SP treatment 
had fallen from above 75% in 1997 to 11% 
by 2000.[25] Retrospective genetic analyses on 
samples collected during a community-based 
prevalence survey in 2000 confirmed the 
presence of highly SP-resistant parasites, with 
47% of all parasites analysed in carrying the 
SP quintuple mutation associated with SP 
treatment failure.[26] This high prevalence of 
SP-resistant parasites most likely enhanced 
transmission, as individuals infected with 
SP-resistant parasites have increased 
gametocyte loads,[27] which are more infectious 
to mosquitoes than SP-sensitive gametocytes.
KZN responded to this SP resistance 
epidemic by becoming the first province 
to deploy the artemisinin-containing 
combination treatment (ACT), AL, in 2001. [24] 
Although malaria morbidity declined by 
99% following this policy change,[24] the SP 
quintuple mutation remained extremely 
prevalent in the province. By 2012, 75% of 
the parasites analysed carried the mutation 
(J Raman, unpublished data). Sustained 
antimicrobial pressure by co-trimoxazole, 
an antifolate-sulphonamide combination 




















































































Fig. 2. Malaria case fatality rates (CFR) in malaria-endemic provinces and the national target, 
1999/2000 season to 2011/2012 season.
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infections in HIV/AIDS patients[28] may be the reason, given the high 
HIV/AIDS prevalence in KZN. 
Encouragingly, however, parasites carrying molecular markers 
associated with CQ sensitivity, namely, crtK76T and mdr186N[29] 
are beginning to resaturate the KZN P. falciparum population.[30] 
A similar phenomenon has been seen in both Mozambique[31] and 
Malawi[32] following the prolonged removal of CQ drug pressure. This 
re-emergence of CQ sensitivity may allow for the use of CQ as an 
antimalarial partner drug in the future.
2.2 Mpumalanga and Limpopo 
Like KZN Province, reports of CQ resistance from Mpumalanga[23] 
and Limpopo provinces[33] first emerged in the 1980s. However, CQ 
treatment failures in both of these provinces remained relatively 
rare until the 1990s. A possible reason for the delay in treatment 
failures is the lower incidence of immigrant asymptomatic malaria 
carriers entering Mpumalanga and Limpopo provinces compared 
with KZN. The border between KZN and Mozambique is extremely 
porous, with people crossing the border on a daily basis.[6] A border-
screening malaria survey in 1996 revealed 58% of the individuals 
entering KZN were asymptomatic malaria carriers who remained 
untreated in the province for long periods, thereby contributing to 
local transmission. [20]
Both in vitro and in vivo studies revealed a growing population 
of CQ-resistant parasites in both Mpumalanga and Limpopo 
provinces[21,34] in the 1990s, which led to SP becoming the 
antimalarial of choice in Mpumalanga Province in 1997 and a year 
later in Limpopo Province. Although therapeutic efficacy studies 
demonstrated sustained SP efficacy in Mpumalanga five years after 
SP introduction,[35] with SP quintuple mutation prevalence only at 
10% (J Raman, unpublished data), patients successfully treated with 
SP displayed enhanced gametocyte carriage.[35] 
In an attempt to reduce gametocyte carriage and malaria case 
numbers the ACT, artesunate-SP, replaced SP as the antimalarial of 
choice in Mpumalanga Province in 2001. While this change resulted 
in the quintuple mutation prevalence declining to <10%, malaria case 
numbers remained largely unchanged in the next few years. The low 
SP quintuple mutation prevalence suggested that something other 
than SP resistance was sustaining malaria transmission.
In accordance with the South African National Malaria Treatment 
guidelines, AL became the first-line treatment in Mpumalanga in 
2006. This policy change was very timely as the SP quintuple mutation 
prevalence had risen to 48% by 2007 (J Raman, unpublished data). 
As seen in KZN, AL introduction resulted in a decline in malaria 
cases, but had no effect on quintuple mutation prevalence. By 2011 
confirmed malaria case numbers had declined by 35% while quintuple 
mutation prevalence has risen to above 80% (J Raman, unpublished 
data). The crt76T and mdr186N molecular markers associated with 
CQ sensitive had become re-established in the population and were 
approaching fixation by 2011 (J Raman, unpublished data).
Although AL became the first-line treatment in Limpopo Province 
in 2004, there was no major decline in malaria case numbers by 2011. 
Unfortunately, drug resistance surveillance data are limited, with only 
one study in 2010 showing quintuple mutation at 41% and <1% of 
parasites analysed carrying markers associated with CQ resistance.
2.3. Regional drug pressure
Despite stringent efforts, drug-resistant malaria epidemics still 
occurred in SA, in part due to the importation of drug-resistant 
parasites. Resistance to both CQ and SP arose in Southeast Asia 
and spread into Africa via gene flow rather than evolving de 
novo,[26,36] highlighting the need for regional malaria control, and 
more importantly, a clear understanding of the malaria epidemiology 
in neighbouring countries. As the movement of both the malaria 
vector and parasite is not restricted by national boundaries regional 
drug pressure can influence drug efficacy within countries, as seen 
in KZN Province, SA[20] and Maputo Province, Mozambique.[37] Given 
the first-line antimalarial in all southern African countries is AL and 
that artemisinin resistance has been confirmed in Southeast Asia,[38] 
routine monitoring of AL efficacy is recommended, particularly 
in Limpopo Province, which currently experiences the highest 
incidence of African immigrant visitors.
3.  Antimalarial drug efficacy 
monitoring and the impact of drug 
resistance on treatment policies
The inevitable emergence and spread of drug resistant parasites has 
had profound effects on South African malaria case management 
strategies. Thus, sustained and rigorous monitoring for antimalarial 
resistance provides the essential backbone for informing evidence-
based malaria treatment policies. During the malaria control phase, 
such monitoring can effectively be conducted through regular in vivo 
therapeutic efficacy studies. Such studies were conducted regularly 
in all three malaria endemic provinces (KZN, Mpumalanga and 
Limpopo) until 2004. These data were complemented by data on 
antimalarial drug exposure and molecular markers of resistance for 
the treatments recommended. In vitro assays have occasionally been 
used to monitor for antimalarial resistance in SA.[21,34] 
The dramatic reductions in local malaria transmission following 
strengthening of vector control and large-scale deployment of ACT 
subsequently precluded an adequate sample size being recruited in 
any sentinel site in SA. Drug resistance monitoring is currently based 
primarily on monitoring for known molecular markers of resistance, 
complemented by surveillance to define geographic and temporal 
trends in malaria case numbers, and routine follow-up of malaria 
cases post-treatment to detect potential treatment failures. 
Malaria treatment policies are decentralised to the provincial 
level, which has resulted in the three malaria endemic provinces 
at times having different policies, as summarised in Table 1. The 
major driver for changes in malaria treatment policies in SA has 
been evidence of parasite resistance to the recommended treatment 
reaching unacceptable levels, as outlined above. Factors usually 
considered for the selection of each new treatment policy include 
recommendations by the WHO, regulatory requirements of the South 
African Medicines Control Council, international peer-reviewed 
evidence on efficacy, safety and tolerability, cost, and likelihood of 
compliance and adherence (including duration and complexity of 
treatment course). 
In KZN, AL was selected as the preferred ACT as there was no 
established resistance to the partner drug, lumefantrine, unlike 
SP or amodiaquine. By contrast, in Mpumalanga and Limpopo, 
where SP remained highly effective, the ACT artesunate-SP was 
selected. This combination had the advantage of not requiring 
co-administration with fat and the majority of patients likely 
to be cured even if they were not fully adherent, given that SP 
treatment only requires a single dose. However, a number of 
disadvantages were detected with careful monitoring following the 
deployment of this combination, including: suboptimal SP exposure 
in young children given the recommended dose of SP (K Barnes, 
unpublished data); that it could not be manufactured as a fixed 
dose combination, and so risked use of artesunate monotherapy; 
and that molecular markers of SP resistance continued to increase 
despite SP being used in combination with artesunate (J Raman, 
unpublished data). 
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However, additional factors have influenced policy and practice. 
The malaria control programme in KZN added a single dose of 
primaquine to SP in the mid-1990s, to reduce transmission. This 
strategy was curtailed when the manufacturer, Winthrop, withdrew 
the product from the South African market. Primaquine is currently 
only available for compassionate use on a named-patient basis.[5] 
Clinicians in KZN started using CQ in addition to SP in the late 1990s 
when they suspected clinically that SP efficacy was waning, although 
no formal resistance studies were conducted.
4. Malaria chemoprophylaxis
Malaria chemoprophylaxis entails the use of antimalarial medicines 
to prevent malaria especially in non-immune people travelling to 
malaria endemic areas.[3] In SA, chemoprophylaxis is recommended 
for residents in non-endemic areas travelling to endemic areas 
within and outside the country.[39] Up until the early 1990s, CQ was 
the recommended antimalarial medicine for chemoprophylaxis. It 
could be given to pregnant women and young children. CQ plus 
pyrimethamine was also used, but in 1991 it was determined that 
due to pyrimethamine resistance, little benefit was conferred by 
the combination. There was an increase in side-effects, and a folic 
acid supplement was necessary when given to pregnant women.[40] 
CQ alone was therefore preferable. Dapsone-pyrimethamine was 
another potential option but had a number of side-effects such as 
agranulocytosis, methaemoglobinaemia and megaloblastic anaemia. 
These, however, were more common when the recommended dose 
was exceeded.[40] There was also concern over efficacy and it was 
therefore not usually officially recommended.[40]
CQ plus proguanil was another option recommended 
internationally; however, proguanil was only registered in SA in 1997, 
at which time the combination became the chemoprophylaxis of 
choice. It was, however, a complicated regime as CQ was taken once 
weekly and proguanil daily. Up until this point, all chemoprophylactic 
options were classified Schedule 1 and could thus be given out 
without a prescription. They were also available from those who were 
employed by any department responsible for environmental affairs or 
tourism at a provincial government level, such as the tourist shops in 
the Kruger National Park.
The emergence of widespread CQ resistance eventually led to 
its abandonment as antimalarial medicine for chemoprophylaxis. 
Thereafter, the selection of antimalarial medicines for 
chemoprophylaxis recommendations in the country has been 
following the WHO recommendations for CQ-resistant malaria 
transmission areas. Currently, doxycycline, mefloquine, and 
atovaquone-proguanil are the recommended choices.[39,41] Unlike CQ 
and the other earlier medicines, these drugs are only available on 
prescription and are not free of charge, even in the public healthcare 
sector.
5.  Considerations for malaria 
elimination
5.1 Drug efficacy monitoring
As countries undergo transition towards malaria elimination, 
routine monitoring of drug efficacy is essential, particularly as 
any artemisinin-resistant malaria outbreak could result in severe 
morbidity and mortality given the low or absent immunity to malaria 
within the population and current dependence on ACT. Conducting 
in vivo efficacy trials in regions approaching malaria elimination is 
virtually impossible due to the low case numbers. Hence, alternative 
methods such as the routine surveillance of molecular resistance 
markers should be considered. Molecular analysis should be 
conducted on samples collected from various sentinel sites to ensure 
robust data is obtained. Technological advances now mean that a 
liquid blood sample is no longer needed for molecular analysis. Filter 
paper blood spots and even malaria-positive RDTs[42] can be used 
as sources of parasite DNA. This routine surveillance must become 
part of the elimination agenda in all South African malaria endemic 
regions, particularly in malaria hot spots.
Inability to monitor for molecular markers of resistance rapidly 
and effectively during the pre-elimination phase is a major threat to 
our ability to eliminate malaria. Drug resistance has almost invariably 
emerged in areas of very low-intensity malaria transmission. As the 
population in these areas is non-immune, infections are usually 
symptomatic so most patients will seek treatment, thereby increasing 
drug pressure. Furthermore, they lack the immunity that is needed to 
suppress replication of resistant parasites. With artemisinin resistance 
already confirmed in four countries in the Greater Mekong Region of 
Southeast Asia, and no molecular marker yet validated for detecting 
artemisinin-resistant parasites, there is a real possibility of this 
resistance spreading to (or emerging in) SA.
Because malaria cases have become too few at any single health facility 
in the endemic provinces in the country, a complete in vivo therapeutic 
efficacy study is not feasible. Until validated molecular markers are 
available for artemisinin resistance, our best options are to continue to 
monitor routinely for molecular markers of resistance to lumefantrine 
(or future ACT partner drugs), and whenever possible to test for the 
presence of P. falciparum parasites 3 days post-treatment, and to follow 
up patients 4 - 6 weeks post-treatment, to establish whether they remain 
malaria-free. The result of the malaria blood smear on day 3 (72 hours 
post-treatment) is a good predictor of subsequent treatment failure, 
and provides a simple screening measure for artemisinin resistance. 
Artemisinin resistance is highly unlikely if the proportion of patients 
with parasite densities of <100  000 parasites/ml, who have a positive 
smear result on day 3 after ACT treatment, is <3%.[43] 
5.2 Radical cure
The malaria situation in SA has now moved from control phase 
to the pre-elimination and elimination phases. ACT policy is fully 
implemented in the country. As malaria becomes less common, 
finding and treating the last few cases becomes increasingly onerous 
and expensive, so it is important to maximise all opportunities for 
interrupting transmission. One such intervention, which is endorsed 
by the WHO,[44] is to treat all positive malaria cases with a single 
dose of primaquine. This drug efficiently inactivates gametocytes 
but in persons with genetically determined glucose-6-phosphate 
dehydrogenase (G6PD) enzyme deficiency of red blood cells, it 
may cause haemolysis and subsequent anaemia of variable severity. 
Historically, the South African black population has a low rate 
of G6PD deficiency, and the enzyme defect locally is generally 
quantitatively fairly mild, so severe reactions are uncommon.[45] 
However, with increasing immigration from other parts of Africa, 
the demographics of G6PD deficiency may have changed. Before the 
elimination programme decides to go ahead with primaquine use, it 
needs to update local knowledge about G6PD deficiency in SA, for 
ethical and scientific reasons.
5.3 Community-level treatment
As part of the malaria elimination programme, SA is seriously 
considering community-level treatment of uncomplicated and 
asymptomatic malaria detected during active case investigation by 
malaria surveillance officers. The feasibility of community-level 
treatment will require extensive training of community health 
workers and malaria field investigators, as well as drug regulatory 
changes, for this to happen. 
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5.4 Free prophylaxis
The currently recommended chemoprophylactic options, which are 
all very effective if taken correctly, are mefloquine, doxycycline and 
atovaquone-proguanil.[39,41] They are all only available on prescription. 
This significantly hinders accessibility by the public. As SA moves 
towards elimination, it will be imperative to make these products 
readily accessible to all those travelling to malaria-risk areas, including 
those who can ill afford chemoprophylaxis. This is important not 
only for reducing the risk of the travellers becoming sick with malaria 
but also for elimination purposes – the prevention of importation 
of parasites into the country which could result in infection of local 
mosquitoes and local malaria transmission.
While there is a strong case and support for the provision of free 
chemoprophylaxis for travellers to malaria-endemic areas for malaria 
elimination purposes, questions around feasibility, cost effectiveness, 
regulation, accessibility and drug scheduling will need to be answered 
before the strategy can be considered in SA.
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